With 20 years of experience managing dedicated funds, we provide institutional investors with tailored access to private markets via three investment strategies:
commitments to primary funds, secondary transactions, and direct equity coinvestments.

Blocs de la page


Healthcare companies: we work alongside the most promising among them to bring their ambitious projects to fruition. Our Healthcare teams work to provide end-to-end support and help turn their vision into reality.

Nov Santé

In 2021, the French Insurance Federation (FFA) and Caisse des Dépôts entrusted Eurazeo with the management of a new healthcare fund called Nov Santé, with the brief of investing in small- and mid-cap healthcare companies and thereby strengthening the French healthcare sector. This €420 million fund was set up in the context of the Covid-19 crisis and makes minority investments of between €10 million and €40 million in the fields of healthcare research, manufacturing and services. With the launch of Nov Santé and its increased stake in Kurma Partners, Eurazeo is confirming its position as a leading investor in the healthcare sector.

  • €420

    millioninvested in the Novsanté Fund

  • €10-40

    millionMax per transaction

Arnaud Vincent portrait
With the management teams, we have the ambition to bring out the true champions of tomorrow, who will contribute to greater health and industrial sovereignty in health systems.
Arnaud Vincent, Managing Director

Kurma Partners

Kurma Partners specializes in providing funding to biotech and healthcare companies. Since 2009, Kurma Partners has been turning the disruptive discoveries of European researchers into leading-edge medicines and medical devices to diagnose and treat seriously ill patients. Its aim is to help these researchers define a plan for validating their discoveries, and to connect them with the best industrial experts and the most experienced entrepreneurs in order to create high-tech companies. Kurma Partners’ teams work alongside promising young companies and help them develop, using their networks and acknowledged expertise in funding innovation in the healthcare and biotech fields. Kurma has already helped create 24 start-ups, and has provided funding to over 55 companies. Many of them have become leaders in their markets.

Latest news


22/01/2024 - PRESS RELEASES

The Nov Santé Actions Non Cotées fund invests in Oncodesign

1 min


17/01/2024 - PRESS RELEASES

The Nov Santé Actions Non Cotées fund invests in Kinvest

1 min


19/09/2023 - TRIBUNE

The revolution in the healthcare sector

5 min

Eurazeo views vignette 3

26/01/2023 - TRIBUNE

Biotechs, the ultimate post-pandemic winners?

5 min

Image Eurazeo Conviction Paper Healthcare

09/01/2023 - PUBLICATIONS

Conviction paper : Healthcare

1 min

Information - Individual investors

Eurazeo Investment Manager (EIM) and Eurazeo Mid Cap (EMC) are merging to form Eurazeo Global Investor (EGI)